Sarhan Hatem A, El-Garhy Omar H, Ali Mohamed A, Youssef Nouran A
Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.
Department of Chest Diseases, Faculty of Medicine, Minia University, Minia, Egypt.
Drug Des Devel Ther. 2016 Jun 9;10:1927-33. doi: 10.2147/DDDT.S103147. eCollection 2016.
Evaluation of the efficacy of nebulized magnesium sulfate (MgSO4) alone and in combination with salbutamol in acute asthma.
A double-blind randomized controlled study was conducted in Chest and Emergency Departments. Thirty patients of acute attack of bronchial asthma were randomized into three groups: MgSO4 nebulization (group A), salbutamol nebulization (group B), and their combination (group C). All patients were monitored before and after nebulization (each 20 minutes) for peak expiratory flow rate (PEFR), respiratory rate (RR), heart rate (HR), blood pressure, pulsus paradoxus, oxygen saturation, clinical examination, and Fischl index.
A highly significant improvement in PEFR, PEFR percentage, and Fischl index and significant decrease in RR and HR was observed in all groups. A similar improvement in PEFR was observed in group A and group B (P=0.389). The difference in peak expiratory flow (PEF) improvement was insignificant between group B and group C (P=0.101), while there was a significant difference between group A and group C (P=0.014) in favor of group C.
Nebulized MgSO4 alone or combined with salbutamol has a clinically significant bronchodilator effect in acute asthma and leads to clinical improvement, increase in PEFR, reduction in HR, and reduction in RR. The response to nebulized MgSO4 alone (PEFR improvement 54±35.6 L/min, P=0.001) is comparable (P=0.389) to that of nebulized salbutamol (PEFR improvement 67.0±41.9 L/min, P=0.001) and is significantly less than (P=0.014) that of nebulized combination (PEFR improvement 92.0±26.9 L/min, P=0.000).
评估雾化硫酸镁(MgSO4)单独使用及与沙丁胺醇联合使用治疗急性哮喘的疗效。
在胸科和急诊科进行一项双盲随机对照研究。30例支气管哮喘急性发作患者被随机分为三组:硫酸镁雾化组(A组)、沙丁胺醇雾化组(B组)及其联合组(C组)。所有患者在雾化前后(每20分钟)监测呼气峰值流速(PEFR)、呼吸频率(RR)、心率(HR)、血压、奇脉、血氧饱和度、临床检查及菲施尔指数。
所有组的PEFR、PEFR百分比和菲施尔指数均有高度显著改善,RR和HR显著降低。A组和B组的PEFR有相似改善(P = 0.389)。B组和C组在呼气峰值流速(PEF)改善方面差异不显著(P = 0.101),而A组和C组之间存在显著差异(P = 0.014),C组更优。
雾化硫酸镁单独使用或与沙丁胺醇联合使用在急性哮喘中具有临床上显著的支气管扩张作用,并导致临床改善、PEFR增加、HR降低和RR降低。单独雾化硫酸镁的反应(PEFR改善54±35.6 L/min,P = 0.001)与雾化沙丁胺醇的反应(PEFR改善67.0±41.9 L/min,P = 0.001)相当(P = 0.389),且显著低于雾化联合组(PEFR改善92.0±26.9 L/min,P = 0.000)。